Jun 2026 (Q2 FY26) — Jul 29, 2026
Bausch Health Q2 FY26 — Strong Growth Across Segments and Raised Full-Year Guidance
Read the full callBausch Health (BHC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Bausch Health earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2,852 | +12.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 25.9 | +8.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 258 | +74.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$6.31 +7.13% · +$0.42
Performance +3.3% 1Y
1Y: $6.11 on 14 Oct 2025 → $6.31. High $7.9 (7 Jan 2026), low $4.43 (24 Jul 2026).
- Previous close
- $5.89
- 52-week range
- $4.43 – $7.9
- One year
- +4.82%
Overview
- Symbol
- BHC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Bausch Health earnings calls (BHC)
Financials
What the filings say
Net profit, year on year: +74% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,510 | 2,559 | 2,259 | 2,530 | 2,681 | 2,796 | 2,524 | 2,852 |
| Expenses | 2,192 | 2,001 | 1,983 | 2,086 | 2,062 | 2,322 | 3,474 | 2,112 |
| Operating profit | 318 | 558 | 276 | 444 | 619 | 474 | -950 | 740 |
| Operating margin | 12.7% | 21.8% | 12.2% | 17.6% | 23.1% | 16.9% | −37.6% | 25.9% |
| Profit before tax | -21 | 209 | -47 | 140 | 218 | 56 | -1,354 | 348 |
| Tax rate | −338.1% | 53.1% | −83.0% | 8.6% | 17.0% | 283.9% | −5.7% | 25.3% |
| Net profit | -85 | 93 | -58 | 148 | 179 | -112 | -1,423 | 258 |
| EPS ($ per share) | -0.23 | — | -0.16 | 0.40 | 0.48 | — | -3.82 | 0.69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 10,121 | 10,172 | 10,227 | 10,317 | 10,391 | 10,423 | 10,490 | 10,516 |
| Reserves | -5,664 | -7,452 | -8,013 | -8,961 | -9,186 | -9,778 | -9,824 | -9,667 |
| Total liabilities | 29,677 | 32,727 | 30,594 | 29,236 | 25,426 | 27,432 | 26,845 | 25,989 |
| Fixed assets | 1,353 | 1,466 | 1,567 | 1,598 | 1,600 | 1,707 | 1,780 | 2,074 |
| Total assets | 32,492 | 33,863 | 31,199 | 29,202 | 25,686 | 27,350 | 26,523 | 26,366 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,501 | 1,501 | 1,111 | 1,426 | -728 | 1,032 | 1,597 | 1,400 |
| Cash from investing | -196 | -419 | -261 | 409 | -303 | -2,145 | -454 | -595 |
| Cash from financing | -1,353 | 1,443 | -2,294 | -1,513 | -474 | 1,475 | -868 | -742 |
| Net cash flow | -74 | 2,521 | -1,428 | 303 | -1,528 | 371 | 239 | 124 |
| Capital expenditure | -157 | -270 | -302 | -269 | -218 | -215 | -337 | -397 |
| Free cash flow | 1,344 | 1,231 | 809 | 1,157 | -946 | 817 | 1,260 | 1,003 |
Insider filings
48 filings between Nov 25, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
$15.63M
1 purchase by 1 insider
Sales
$506.7K
5 sales by 3 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 28
- Award — granted as compensation
- 12
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| PAULSON & CO. INC. | $15.63M | — | Nov 25, 2025 |
| Lenar Aimee J. | — | $258.9K | Aug 19, 2026 |
| Lee Frank D. | — | $132.8K | May 19, 2026 |
| Carson Seana | — | $115.0K | Mar 3, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Paulson John Director | Award | 10,720 | $62.5K |
| Sep 30, 2026 | LEUNG SANDRA Director | Award | 5,789 | $33.7K |
| Sep 30, 2026 | WECHSLER AMY B Director | Award | 1,179 | $6.9K |
| Aug 19, 2026 | Lenar Aimee J. President, US Pharma | Sale 10b5-1 plan | 36,827 | $258.9K |
| Jul 17, 2026 | Lenar Aimee J. President, US Pharma | Tax withheld | 5,260 | $25.4K |
| Jul 15, 2026 | Lenar Aimee J. President, US Pharma | Tax withheld | 23,395 | $114.4K |
| Jul 14, 2026 | LEE STEVEN HYOSIG SVP, Controller & CAO | Tax withheld | 3,125 | $14.8K |
| Jun 30, 2026 | WECHSLER AMY B Director | Award | 1,394 | $6.9K |
| Jun 30, 2026 | Paulson John Director | Award | 12,677 | $62.5K |
| Jun 30, 2026 | LEUNG SANDRA Director | Award | 6,845 | $33.7K |
| May 22, 2026 | POWER ROBERT N Director | Award | 45,871 | $0 |
| May 22, 2026 | Paulson John Director | Award | 45,871 | $0 |
| May 22, 2026 | LEUNG SANDRA Director | Award | 45,871 | $0 |
| May 22, 2026 | ROBERTS EIRY Director | Award | 45,871 | $0 |
| May 22, 2026 | Lee Frank D. Director | Award | 45,871 | $0 |
| May 22, 2026 | KAVANAGH SARAH B Director | Award | 45,871 | $0 |
| May 22, 2026 | GOETTLER MICHAEL Director | Award | 45,871 | $0 |
| May 22, 2026 | Garcia Christian A Director | Award | 45,871 | $0 |
| May 22, 2026 | WECHSLER AMY B Director | Award | 45,871 | $0 |
| May 19, 2026 | Lee Frank D. Director | Sale 10b5-1 plan | 24,456 | $132.8K |
| Mar 31, 2026 | Paulson John Director | Award | 11,574 | $62.5K |
| Mar 31, 2026 | WECHSLER AMY B Director | Award | 1,273 | $6.9K |
| Mar 31, 2026 | LEUNG SANDRA Director | Award | 5,946 | $32.1K |
| Mar 3, 2026 | Carson Seana EVP, General Counsel | Sale 10b5-1 plan | 4,420 | $25.5K |
| Mar 2, 2026 | Carson Seana EVP, General Counsel | Other 10b5-1 plan | 137,922 | $820.6K |
| Mar 2, 2026 | Carson Seana EVP, General Counsel | Tax withheld 10b5-1 plan | 16,973 | $101.0K |
| Mar 2, 2026 | Carson Seana EVP, General Counsel | Sale 10b5-1 plan | 6,856 | $39.6K |
| Mar 2, 2026 | APPIO THOMAS Chief Executive Officer | Other | 1,137,862 | $6.77M |
| Mar 2, 2026 | APPIO THOMAS Chief Executive Officer | Tax withheld | 83,705 | $498.0K |
| Feb 27, 2026 | Charhon Jean-Jacques EVP, CFO | Tax withheld | 49,060 | $290.9K |
| Feb 27, 2026 | Carson Seana EVP, General Counsel | Tax withheld 10b5-1 plan | 26,326 | $156.1K |
| Feb 27, 2026 | APPIO THOMAS Chief Executive Officer | Tax withheld | 83,093 | $492.7K |
| Feb 27, 2026 | Carson Seana EVP, General Counsel | Sale 10b5-1 plan | 8,388 | $49.9K |
| Feb 26, 2026 | APPIO THOMAS Chief Executive Officer | Tax withheld | 116,502 | $703.7K |
| Feb 26, 2026 | Lenar Aimee J. EVP, US Pharma | Tax withheld | 17,578 | $106.2K |
| Feb 26, 2026 | Carson Seana EVP, General Counsel | Tax withheld 10b5-1 plan | 32,211 | $194.6K |
| Feb 26, 2026 | Charhon Jean-Jacques EVP, CFO | Tax withheld | 35,977 | $217.3K |
| Feb 25, 2026 | Charhon Jean-Jacques EVP, CFO | Award | 276,055 | $0 |
| Feb 25, 2026 | APPIO THOMAS Chief Executive Officer | Award | 815,425 | $0 |
| Feb 25, 2026 | LEE STEVEN HYOSIG SVP, Controller & CAO | Award | 45,868 | $0 |
| Feb 25, 2026 | Lenar Aimee J. EVP, US Pharma | Award | 157,139 | $0 |
| Feb 25, 2026 | Carson Seana EVP, General Counsel | Award 10b5-1 plan | 212,350 | $0 |
| Feb 9, 2026 | Carson Seana EVP, General Counsel | Award | 137,922 | $0 |
| Feb 9, 2026 | APPIO THOMAS Chief Executive Officer | Award | 1,137,862 | $0 |
| Dec 31, 2025 | Paulson John Director | Award | 8,992 | $0 |
| Dec 31, 2025 | LEUNG SANDRA Director | Award | 4,586 | $0 |
| Dec 31, 2025 | WECHSLER AMY B Director | Award | 989 | $0 |
| Nov 25, 2025 | PAULSON & CO. INC. 10% owner | Purchase | 2,500,000 | $15.63M |
| Sep 30, 2025 | Paulson John Director | Award | 9,689 | $0 |
| Sep 30, 2025 | WECHSLER AMY B Director | Award | 1,065 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Bausch Health Companies Inc.
Free account. Everything above stays public.
Write why you follow Bausch Health Companies Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading